Switch to dolutegravir is well tolerated in Thais with HIV infection
Abstract
Dolutegravir (DTG) is recommended as part of first‐line antiretroviral therapy (ART) for people living with HIV(PLHIV). We sought to determine the rate of adverse events (AEs) and discontinuations among Thais treated during acute HIV infection (AHI) and switched to DTG‐based regimens.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 01, 2019
- Source ID
- 10.1002/jia2.25324
Entities
People
- Carlo Sacdalan
- Donn J. Colby
- Duanghathai Suttichom
- Eugène Kroon
- Jintanat Ananworanich
- Merlin L Robb
- Nitiya Chomchey
- Nittaya Phanuphak
- On Behalf Of Rv254/search 010 Study Group
- Orlanda Q Goh
- Peeriya Prueksakaew
- Phillip Chan
- Praphan Phanuphak
- Rapee Trichavaroj
- Ratchapong Kanaprach
- Serena Spudich
- Suteeraporn Pinyakorn
Organizations
- Armed Forces Research Institute of Medical Sciences
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Johns Hopkins Bloomberg School of Public Health
- Thai Red Cross Society
- United States Department of Defense
- University of Amsterdam
- Walter Reed Army Institute of Research
- Yale University